BioSpace News Archive

Career Advice

Top Interview Pet Peeves from Hiring Managers

Many hiring managers agree on candidate interview behaviors that annoy them – sometimes to the extent of sinking the interviewee’s chances.

December 23, 2019
·
4 min read
·
Katharine Hansen, PhD
FDA

FDA Gives Thumbs-Up to Enhertu for Hard-to-Treat HER2+ Breast Cancer

Specifically, it was approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.

December 23, 2019
·
2 min read
·
Mark Terry
FDA

ViiV Receives CRL for Combination HIV Treatment

The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.

December 23, 2019
·
2 min read
·
Alex Keown
Business

Roche and Sarepta Partner on Duchenne Muscular Dystrophy Therapy

Sarepta Therapeutics and Roche inked a licensing deal that gives Roche exclusive commercial rights to SRP-9001, Sarepta’s investigation gene therapy for Duchenne muscular dystrophy, outside the U.S.

December 23, 2019
·
2 min read
·
Mark Terry
Atopic Dermatitis Space Will Heat Up in 2020, Analyst Predicts

The future of the atopic dermatitis space is going to be a competitive one. Multiple assets are in line to be submitted for regulatory approval and will, if approved, challenge the leading market share currently held by Regeneron and Sanofi’s Dupixent.

December 23, 2019
·
3 min read
·
Alex Keown
Drug Development

BioSpace Global Roundup, Dec. 26

Companies from across the globe provide updates on their business and pipeline progress.

December 23, 2019
·
6 min read
·
Alex Keown
Business

BioSpace Movers & Shakers, Dec. 27

Pharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.

December 23, 2019
·
2 min read
·
Alex Keown
FDA

FDA Gives Greenlight to Eisai’s Dayvigo for Insomnia

The clinical trials the approval is based on suggested the drug was effective for treating primary insomnia but may also be effective for insomnia associated with other diseases, such as depression.

December 23, 2019
·
3 min read
·
Mark Terry
Business

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.

December 23, 2019
·
2 min read
·
Alex Keown
BioForest

Top 10 Biopharma Stories of 2019

This year marked yet another series of interesting, exciting and occasionally puzzling stories coming out of the biopharma industry. Our breaking news writers, Alex Keown and Mark Terry, picked their top 10 stories of the year.

December 23, 2019
·
11 min read
·
Mark Terry and Alex Keown